Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Traboulsee

Greenberg

Bennett

, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19(5): 402–412.

Yamamura

Kleiter

Fujihara

, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381: 2114–2124.

Yamamura

Weinshenker

Yeaman

, et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord 2022; 66: 104025.

US Food and Drug Administration. Genentech. Enspryng® (satralizumab) [package insert]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf (accessed 13 October 2022).

European Medicines Agency. Enspryng® (satralizumab) [package leaflet]. https://www.ema.europa.eu/en/documents/product-information/enspryng-epar-product-information_en.pdf (accessed 13 October 2022).

Severe febrile neutropenia associated with satralizumab in an Argentinian NMOSD patient—Commentary

Abstract

Get full access to this article

References